Clinical trial · Observational
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
Association Between Tumour Amphiregulin, Epiregulin and Epidermal Growth Factor Receptor (EGFR) Expression and Response to Anti-EGFR Agents in Colorectal Cancer
NCT03986541CI-TRIAL-00077474completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Observational study investigating the relationship between tumour amphiregulin, epiregulin and epithelial growth factor receptor expression and response to anti-EGFR agents in advanced colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer Stage IV | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemistry | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Retrospective cohort
- description
- Patients with advanced colorectal cancer previously treated with an anti-EGFR agent (panitumumab or cetuximab).
- interventionNames
- Diagnostic Test: Immunohistochemistry
- label
- Prospective cohort
- description
- Patients with advanced colorectal cancer newly starting treatment with an anti-EGFR agent (panitumumab or cetuximab).
- interventionNames
- Diagnostic Test: Immunohistochemistry
Primary outcomes (1)
- measure
- Progression free survival
- timeFrame
- March 2023
- description
- PFS will be calculated from date of commencing treatment to date of progression or death from any cause (whichever is sooner). Time of progression will be determined clinically or radiologically by the participant's treating oncologist.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven advanced colorectal adenocarcinoma at time treatment commenced (either inoperable metastatic disease at diagnosis or inoperable recurrent disease) * Aged 18 or over at time treatment commenced * The patient has received or has consented to receive treatment with cetuximab or panitumumab Exclusion Criteria: * Stage I, II or III colorectal adenocarcinoma * RAS mutant disease * Eligible for potentially curative surgery (prospective cohort) * Underwent cancer surgery subsequent to anti-EGFR therapy (retrospective cohort) * Unable to provide informed consent (with the exception of patients in the retrospective cohort who have passed away)
References
Publications (0)
Data not yet available
No reference posted for this study.